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DOPAMINE EFFECTS OF STIMULANT AND NON-STIMULANT DRUGS USED IN THE 
TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER 
 
 
Preeti Chalwadi 
74 Pages 
Attention deficit hyperactivity disorder (ADHD) is thought to be associated with 
dysfunction of ascending catecholamine neuronal systems, particularly dopamine (DA) and 
norepinephrine (NE). Dysfunction of these catecholamine neurons innervating the prefrontal 
cortex is hypothesized to underlie impaired executive functions. Dysfunction of the DA neurons 
innervating the striatum is additionally hypothesized to underlie deficits in motivation and 
reinforcement learning. However, mechanisms of action of therapeutic drugs used for treating 
ADHD have mainly focused on catecholamines in the prefrontal cortex and have not adequately 
addressed the role played by DA signaling in the striatum. Stimulants such as Adderall® and 
Ritalin® are chemically considered “amphetamines”. While effective for treating ADHD, there 
are grave concerns about stimulant abuse with this drug class. The more recently developed 
Strattera®, a non-stimulant used to treat AHDH, offers a non-addictive alterative. However, how 
Strattera® acts pharmacologically in the brain is not completely established. Our study 
investigates the brain mechanisms of Strattera® and specifically examines how Strattera® acts on 
brain dopamine neurons, which are important for learning. The second part of the study 
investigates the mechanism of action of the stimulant class of drugs. Stimulants act on brain 
dopamine neurons by blocking a protein that removes dopamine after its release to terminal 
neurotransmission. This action is thought to underlie the addictive potential of stimulants. We are 
pursuing a novel action of stimulants: increasing the dopamine released by action potential 
dependent exocytosis. This action would increase brain dopamine, thereby mediating some of the 
pharmacological effects of stimulants. Collectively, our studies provide insight into how important 
drugs used clinically and often are abused act on the brain. The long-term goal is to distinguish 
the clinically efficacious component of these drugs from their addictive potential, which should 
help drive development of safer drugs for treating ADHD. 
KEYWORDS: Dopamine; Atomoxetine; Psychostimulants; Amphetamine; Modafinil; Cocaine; 
Phasic dopamine signaling; Transients; DAT-inhibitor. 
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CHAPTER I 
EFFECT OF ATOMOXETINE ON PHASIC DOPAMINE SIGNALING 
Abstract 
Attention deficit hyperactivity disorder (ADHD) is thought to be associated with 
dysfunction of ascending catecholamine systems in the brain, particularly dopamine (DA) and 
norepinephrine (NE). Dysfunction of these catecholamine neurons innervating the prefrontal 
cortex is hypothesized to underlie impaired executive functions. Dysfunction of the DA neurons 
innervating the striatum is additionally hypothesized to underlie deficits in motivation and 
reinforcement learning. However, investigating mechanisms of action of therapeutic drugs used 
for treating ADHD has mainly focused on catecholamines in the prefrontal cortex and have not 
adequately addressed the role played by DA signaling in the striatum. The present study addresses 
this issue by examining the neuropharmacologic mechanism of atomoxetine (ATX), a potent and 
selective NE reuptake inhibitor, on phasic DA signaling in the striatum of anesthetized rats. ATX, 
a non-stimulant approved for ADHD treatment in the form of Strattera®, is suggested to produce 
its therapeutic effects by enhancing catecholamine transmission in the prefrontal cortex. We 
propose that in addition to its remedial effects in the prefrontal cortex, ATX enhances phasic DA 
signaling in the striatum. We found ATX to activate DA transients, the extracellular component 
of phasic DA signaling occurring in DA terminal fields and elicited by burst firing of DA neurons, 
which were measured by fast-scan cyclic voltammetry at a carbon-fiber microelectrode. This study 
is neurobiologically significant, because it leads to a better understanding of the role NE plays in 
regulating phasic DA signaling in the striatum. Moreover, this study sheds light on the 
incompletely understood therapeutic mechanism of action of ATX and hence, may contribute 
towards development of better drugs for treating ADHD. 
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Introduction 
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder with an 
onset in childhood and can continue into adolescence and adulthood. 5% of the children in the 
United States have ADHD (American Psychiatric Association, 2013). According to the DSM-5, 
ADHD is characterized by insufficient levels of attention and high levels of impulsivity and 
hyperactivity. These symptoms have been linked to deficits in executive function, response 
inhibition, and reinforcement learning, which in turn result from an underlying brain dysfunction, 
particularly the prefrontal cortex (PFC) and the striatum. While the PFC is involved in executive 
functions, such as inhibition of inappropriate behavior, planning, organization, and attention 
(Arnsten & Li, 2005), the striatum is important in processing reward-related information (Apicella 
et al., 1991; Kawagoe et al., 1998). Various imaging studies have pointed towards hypo-functional 
PFC (Castellanos et al., 1996) and striatal activity as pivotal pathophysiologic features of ADHD 
(Aston-Jones et al., 2000; Lou et al., 1989). The catecholamines, specifically dopamine (DA) and 
norepinephrine (NE), and their dysfunctional modulation of the prefrontal and striatal circuits are 
the principal neuropharmacologic target in treating ADHD (Castellanos & Tannock, 2002).  
Models of ADHD pathophysiology include the inverted-U model, which describes PFC 
function and dysfunction using an inverted-U dose-response curve for both DA and NE (Levy, 
2009). It hypothesizes that in individuals with ADHD, catecholamines are present at lower than 
optimal levels. Low catecholamine levels result in an underactive PFC, due to diminished 
activation of the D1 and α-2 adrenergic receptors by DA and NE, respectively (Aston-Jones et al., 
2000; Arnsten & Pliszka, 2011). Another model, called the dopamine transfer deficit (DTD) 
model, addresses the role of the striatum in ADHD. The DTD model describes a neuronal 
mechanism whereby ADHD patients show altered reinforcement learning, during which the 
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reward (reinforcer) becomes associated with a predictive cue over time (Berridge, 2001). Early in 
reinforcement learning, the DA transient, an extracellular phasic signal initially elicited by the 
reward activating burst firing of DA neurons (Schultz, 1998), is transferred in part, to the 
predictive stimulus, but it also remains activated by the reward itself. Later in learning, the DA 
transient is solely elicited by the predictive cue (Tripp & Wickens, 2008). The DTD model 
proposes that in individuals with ADHD, this transfer of the DA transient from the reward to the 
cue is disturbed, such that the cue-evoked DA transient is weak, leading to ineffective 
reinforcement learning (Tripp & Wickens, 2008).  
Medications approved by the Food and Drug Administration for treating ADHD include 
psychostimulants, such as amphetamine (AMPH; Adderall) and methylphenidate (MPH; Ritalin), 
and more recently, a non-stimulant, atomoxetine (ATX; Strattera®) (Bymaster et al., 2002). All 
of these ADHD drugs increase extracellular NE and DA concentrations in the brain by blocking 
their uptake; specifically, AMPH and MPH block the NE transporter (NET) and the DA 
transporter (DAT), whereas ATX selectively inhibits NET. In terms of therapeutic implications 
of the inverted-U model, it is suggested that ADHD drugs elevate extracellular levels of DA and 
NE in the PFC and hence, improve PFC functionality (Arnsten, 2006). Microdialysis studies show 
that ATX, AMPH, and MPH increase NE and DA levels in the PFC (Bymaster et al., 2002; 
Berridge & Stalnaker, 2002; Berridge & Stalnaker, 2002; Berridge & Stalnaker, 2002). While 
AMPH and MPH also increase extracellular DA in the striatum (Kuczenski & Segal, 2001; 
Berridge et al., 2006), ATX does not (Bymaster et al., 2002). Taken together, these results suggest 
that ADHD drugs elicit these catecholamine effects preferentially, and in the case of ATX, 
exclusively, in the PFC. However, microdialysis has limited temporal resolution, preventing the 
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assessment of the effects of these drugs on DA transients (Borland et al., 2005; Robinson et al., 
2003), whose dysfunction is implicated in the DTD model of ADHD. 
Work in anesthetized rats suggests that ADHD drugs also activate burst firing of DA 
neurons. For example, in vivo electrophysiological recordings have shown AMPH and MPH to 
elicit burst firing of VTA DA neurons (Shi et al., 2004). AMPH-induced burst firing of DA 
neurons was blocked following administration of the α1 NE antagonist, prazosin (Shi et al., 2000; 
Shi et al., 2004). Furthermore, AMPH administration failed to produce burst firing of DA neurons 
following a forebrain hemisection, severing neuronal projections from the PFC to the midbrain 
(Shi et al., 2004). Taken together, these results suggest that NE is an important mediator of the 
DA effects of psychostimulants and that PFC afferents to the VTA contribute to eliciting burst 
firing of the DA neurons. High-affinity NET inhibitors such as nisoxetine and reboxetine, which 
increase PFC NE levels, also activate DA neuron burst firing (Shi et al., 2000; Linner et al., 2001). 
Thus, ADHD medications may elicit their therapeutic effects, at least in part, through activation 
of DA neuron burst firing facilitated by increased NE levels and α-1 receptor activation in the 
PFC. This activation of DA cell burst firing should in turn give rise to DA transients in the ventral 
striatum, a hypothesis not tested to date.  
Previous work in our lab using fast-scan cyclic voltammetry (FSCV) at a carbon-fiber 
microelectrode (CFM), which exhibits the requisite temporal and chemical resolution to monitor 
DA transients with high fidelity (Roberts et al., 2013), has shown AMPH to elicit DA transients 
in the striatum (Daberkow et al., 2013; Ramsson et al., 2011; Covey et al., 2013). Whether ATX 
also elicits DA transients in this brain region is not known. Psychostimulant ADHD drugs, such 
as AMPH, also have presynaptic effects at DA terminals. Not only do they decrease DA uptake, 
in keeping with their well-recognized role as DAT inhibitors, but recent evidence suggests that 
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they also increase exocytotic DA release (Covey et al., 2013; Daberkow et al., 2013). In the present 
study, we thus wanted to investigate whether ATX similarly alters presynaptic DA mechanisms 
and DA transients in the striatum. Here we use FSCV at a CFM to monitor electrically evoked 
phasic-like DA signals and DA transients. We also used this analytical technique coupled to a 
chemometrics approach to monitor changes in basal DA levels in the striatum in order to compare 
with previous microdialysis measurements characterizing ATX action. We found that ATX 
activates DA transients in the ventral striatum without altering presynaptic DA mechanisms, as 
reflected by electrically evoked phasic-liked DA signals and basal DA levels. Taken together, our 
results suggest that in addition to increasing PFC levels of DA and NE, ATX activates phasic DA 
signaling in the striatum, which could be a novel mechanism mediating its therapeutic efficacy in 
treating ADHD. 
Materials and Methods 
Animals 
Adult Sprague-Dawley rats (350-500g) were purchased from Harlan (Indianapolis, IN, 
USA) and housed in a light- and temperature-controlled vivarium. Access to food and water was 
provided ad libitum. All procedures were in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and were approved by the Institutional 
Animal Care and Use Committee of Illinois State University. 
Surgery 
Adult male Sprague-Dawley rats were anesthetized with urethane (1.6 g/kg, i.p.) and 
mounted in a stereotaxic apparatus. An incision of the scalp was made, and skin and fascia 
removed. Holes for reference, stimulating, and recording electrodes were drilled through the skull. 
All coordinates, anteroposterior (AP), mediolateral (ML) and dorsoventral (DV), are given in mm 
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and are referenced to bregma (Paxinos & Watson, 2007). The stimulating electrode was placed in 
the medial forebrain bundle (MFB; -4.6 AP, +1.3 ML, -7.5 DV), a CFM targeted the ipsilateral 
ventral striatum (+1.2 AP, +1.5 ML, -6.5 DV), and the Ag/AgCl reference electrode was placed 
superficially in the contralateral cortex. Final positions of the CFM and stimulating electrode were 
based on optimizing the electrically evoked DA signal and were fixed for the duration of the 
experiment. 
Experimental design 
As shown in Figure 1, two experimental designs were used in the present study. In both 
designs, DA signals were recorded in 5-min epochs and when applied, electrical stimulation 
occurred 5 s into the epoch. Design 1 was used for a pilot set of experiments with drugs 
administered i.p. (Fig. 1A). In Design 1a, three pre-drug epochs were followed by twelve ATX 
(10 mg/kg), twelve RAC (0.2 mg/kg), and thirteen AMPH (10 mg/kg; administered along with a 
second dose of RAC (0.2 mg/kg); positive control) epochs. The order of RAC and ATX 
administration was reversed for Design 1b. Electrical stimulation was applied into each pre-drug 
epoch, and 30- and 60-min post-drug epochs. These epochs were analyzed for electrically evoked 
phasic-like DA signals and DA transients. Figure 1B shows Design 2, which was used for the 
remainder of the experiments with drugs administered i.v. In Design 2a, three pre-drug epochs 
were followed by two saline (SAL, negative control), two ATX (10 mg/kg), two raclopride (RAC, 
0.1 mg/kg), and three AMPH (1 mg/kg; positive control) epochs. The order of RAC and ATX 
administration was reversed for Design 2b. Electrically evoked phasic-like DA signals, DA 
transients, and changes in basal DA levels were evaluated for each epoch. 
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Electrochemistry 
DA was recorded using FSCV at a CFM (Roberts et al., 2013). A triangular waveform (-
0.4 to 1.3 V and back, 400 V/s) was applied to the CFM every 100 ms. CFMs were prepared by 
aspirating a single carbon fiber (r = 2.5 μm) into a borosilicate capillary tube (1.2 mm o.d.; Sutter 
Instruments, Novato, CA, USA) and pulling to a taper using a micropipette puller (Narishige, 
Tokyo, Japan). The carbon fiber was then cut to ~100 µm distal to the glass seal. A Universal 
Electrochemistry Instrument (Department of Chemistry Electronic Shop, University of North 
Carolina, Chapel Hill, NC, USA) and commercially available software (ESA, Chelmsford, MA, 
USA) were used to perform FSCV. CFMs were calibrated in a modified TRIS buffer (Kume-Kick 
& Rice, 1998; Wu et al., 2001) after each experiment to convert the current recorded at the peak 
oxidative potential for DA (~+0.6 V) to concentration (Wightman et al., 2007). DA was initially 
identified by the background subtracted voltammogram (Michael et al., 1998; Heien et al., 2004). 
In experiments assessing effects of MOD on basal DA and DA transients, DA was additionally 
identified using principal component regression (PCR; see below).  
Electrical stimulation 
Biphasic stimulation pulses (2 ms each phase) were applied to a twisted bipolar stimulating 
electrode (Plastics One, Roanoke, VA, USA), with tips spaced ~1 mm apart. Stimulus pulses were 
optically isolated and constant current (Neurolog NL800; Digitimer Limited, Letchworth Garden 
City, UK), and delivered as 60-Hz, 24-pulse trains with a current intensity of ±300 µA. 
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Data analysis 
Figures 1C and D conceptually describe data analyses. To quantify changes in basal DA 
(Δ[DA]) and DA transients, the FSCV record was first processed by PCR to resolve DA from the 
interferents, pH and background drift (Howard et al., 2013; Covey et al., 2016). PCR-resolved 
epochs were accepted if any current not accounted for by the retained principal components of the 
training sets, or residual (Q), was less than the 95% confidence threshold (Qα). Δ[DA] was 
calculated by averaging all data in the PCR-resolved DA trace of each 5-min epoch after the 
baseline has stabilized following electrical stimulation and noise artifacts generated by drug 
injection (Fig. 1C, right and left panels). DA transients in the PCR record were identified as peaks 
in the non-electrically evoked record greater than 5-times the root-mean-square noise, using peak-
finding software (Mini-Analysis, Synaptosoft, Decatur, GA) (Fig. 1C, INSET). The maximal 
amplitude of electrically evoked phasic-like DA signals ([DA]max) was analyzed to quantify drug 
effects on presynaptic DA mechanisms (Fig. 1D). [DA]max was determined from the raw FSCV, 
because at short times DA is the predominant analyte monitored by FSCV with MFB stimulation 
(see Fig. 1C). 
Statistics 
When appropriate, data are presented as the mean ± SEM. One-way repeated-measures 
ANOVA, with time or drug as the factor and repeated measures, was used to assess drug effects 
on [DA]max, DA transients, and Δ[DA]. Post-hoc comparisons employed the Sidak test. All 
statistical analyses were performed using SAS, and significance was set at p < 0.05. 
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Drugs and chemicals 
Atomoxetine hydrochloride was kindly provided by the Lilly Research Laboratories, 
Indianapolis, IN. Raclopride and D-amphetamine were purchased from Sigma (St. Louis, MO, 
USA). 
Results 
I.p. drug administration 
Pilot experiments assessing i.p. drug administration were performed using Design 1 shown 
in Figure 1A. The order of drug administration in Design 1a (n = 2) was ATX, RAC, and AMPH. 
The order of ATX and RAC was reversed in Design 1b (n = 2). Figure 2A shows representative 
FSCV recordings demonstrating the effects of ATX, RAC, and AMPH on electrically evoked 
phasic-like DA signals measured in the ventral striatum. These evoked DA responses recorded 
under pre-drug conditions are considered phasic-like, because they emulate the amplitude and 
dynamics of naturally occurring DA transients (Robinson et al., 2008). The individual 
voltammogram (INSET in each panel) and pseudo-color plot displaying all voltammograms 
collected during the measurement in time (below each [DA] versus time recording) indicate that 
DA was the predominate analyte evoked by MFB stimulation for pre-drug and drug conditions. 
Compared to the pre-drug recording, RAC increased the maximal amplitude of the electrically 
evoked DA signal ([DA]max) and its duration. While ATX did not alter [DA]max or the dynamics 
of this signal, AMPH further enhanced its [DA]max and duration. 
Drug effects on [DA]max were analyzed by combining the time series of [DA]max (i.e., 
repeating 5-min epochs) into drug groups, as shown in Figure 2B. One-way repeated measures 
ANOVA with pseudo-replication was performed and revealed significant effects of drug on 
[DA]max for Design 1a (F3,3 = 56.53, p = 0.0039). Post-hoc tests revealed no significant increase 
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in [DA]max with ATX (p = 1.0), whereas both RAC (p = 0.047) and AMPH (p < 0.0001) 
significantly increased [DA]max compared to pre-drug control. Consistent with representative 
recordings, Design 2 showed a significant effect of drug (F3,3 = 81.55, p = 0.0023), and post-hoc 
tests showed that RAC significantly increased [DA]max (p < 0.0001), but ATX and AMPH did not 
bring about any further increase. Taken together, the results suggest that ATX administered i.p. 
either in the presence or absence of RAC does not alter electrically evoked phasic-like DA signals 
recorded in the ventral striatum. 
We also failed to detect any DA transients in response to ATX or RAC with i.p. 
administration, as shown in the representative recordings in Figure 2C. Only AMPH, which was 
used as a positive control, and when co-administered with a second dose of RAC, elicited DA 
transients. Similar results were found across all animals in Design 1a and Design 1b. While the 
lack of presynaptic DA effects of ATX in the striatum was expected, the lack of ATX effects on 
DA transients was not and could be due to slow drug adsorption with the i.p. route of 
administration. Because drug adsorption is about twice as high for i.v. of administration 
(Woodard, 1965), we investigated ATX effects with this route using Designs 2a and 2b (Figure 
1B, n = 4 and 4, respectively) for the remainder of the study.  
ATX does not alter electrically evoked phasic-like DA signals 
Figure 3A shows representative recordings demonstrating the effects of SAL, ATX, RAC, 
and AMPH on electrically evoked phasic-like DA responses measured in the ventral striatum 
following i.v. administration and using Design 2a. The individual voltammograms (INSET in each 
panel) and pseudo-color plot displaying all voltammograms collected during the measurement in 
time (below each [DA] versus time recording) indicate that DA is the predominant analyte evoked 
by MFB stimulation for pre-drug and drug conditions. ATX did not alter [DA]max or the dynamics 
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of the evoked response compared to SAL. In contrast, both RAC and AMPH increased [DA]max 
and its duration. AMPH appeared to further enhance the RAC-altered evoked response. 
Figure 3B shows average values of [DA]max for each 5 min-epoch and expressed as a 
percent change from the pre-drug condition. One-way repeated measures ANOVA revealed a 
significant effect of time for Design 2a (left panel; F11,44 = 9.02, p < 0.0001) and Design 2b (right 
panel; F11,33 = 4.78, p = 0.0002). To further analyze drug effects, the time series of [DA]max shown 
in each 5-min epoch was compiled into drug groups in Figure 3C. Because post-hoc tests revealed 
no significant differences between pre-drug and SAL groups, a single control for [DA]max was 
created by combining both groups. One-way repeated measures ANOVA with pseudo-replication 
revealed a significant effect of drug on [DA]max for Design 2a (left panel; F3,56 = 32.14, p < 
0.0001). Post-hoc tests revealed no significant increase in [DA]max with ATX (p = 0.7786), 
whereas both RAC (p = 0.0001) and AMPH (p < 0.0001) significantly increased [DA]max 
compared to control and ATX. A significant effect of drug was also found for Design 2b (right 
panel; F3,32 = 10.57, p < 0.0001), and post-hoc tests showed that while RAC significantly increased 
[DA]max (p = 0.0055), ATX and AMPH did not bring about any further increase. Thus, consistent 
with i.p. administration, i.v. ATX did not alter electrically evoked phasic-like DA signals. Taken 
together, these results suggest that ATX does not act presynaptically on striatal DA terminals. 
ATX activates DA transients 
Figure 4A shows representative recordings demonstrating the effects of SAL, ATX, RAC, 
and AMPH on DA transients in the ventral striatum following i.v. administration and using Design 
2a. Each panel shows a PCR-resolved [DA] versus time recording with transients denoted by a 
red asterisk. Above each recording are individual voltammograms comparing transients (or 
baseline; red) to the electrically evoked signal (black). Below each recording is the pseudo-color 
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plot showing all voltammograms collected during the measurement in time. Whereas no DA 
transients were observed in the SAL recording, DA transients were present after ATX, RAC, and 
AMPH administration. Voltammograms confirm DA as the origin of these transients.  
Figure 4B shows the average number of DA transients for each 5 min-epoch. One-way 
repeated measures ANOVA revealed a significant effect of time for Design 2a (left panel; F11,33 = 
6.03, p < 0.0001) and Design 2b (right panel; F11,33 = 6.86, p < 0.0001). Similar to the analysis of 
[DA]max above, the time series of DA transients was compiled into drug groups with a single 
control in Figure 4C. One-way repeated measures ANOVA with pseudo-replication revealed a 
significant effect of drug on DA transients for Design 2a (left panel; F3,9 = 22.07, p = 0.0002). 
Post-hoc tests revealed a significant increase in DA transients with ATX (p = 0.0039), RAC (p = 
0.0001), and AMPH (p < 0.0001) compared to control. A significant effect of drug was also found 
for Design 2b (right panel; F3,9 = 18.46, p = 0.0003). Post-hoc tests revealed a significant increase 
in DA transients with ATX (p < 0.0001) and AMPH (p < 0.0001) but not RAC (p = 0.1765) 
compared to control and that AMPH increased DA transients compared to RAC (p = 0.0102). 
Taken together, these results suggest that ATX elicits DA transients in the ventral striatum with 
and without RAC. 
ATX and basal DA 
Figure 5A shows representative recordings demonstrating the effects of SAL, ATX, RAC, 
and AMPH on the change in basal (i.e., non-electrically evoked) DA levels in the ventral striatum 
following i.v. administration and using Design 2a. Each panel shows a raw FSCV (black) and 
PCR-resolved (red) [DA] versus time recording. Below each recording is the pseudo-color plot 
showing all voltammograms collected during the measurement in time. For the SAL trace, there 
appears to be minimal changes in the FSCV record and not unexpectedly, considerable overlap 
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with the PCA-resolved record. For ATX, RAC, and AMPH, there appears to be a steady decrease 
in the FSCV signal after drug injection, with more pronounced effects for RAC and AMPH and 
indicative of the non-DA changes in the pseudo-color plots. PCR processing produced no change 
in basal DA levels with ATX, but revealed increases with RAC and AMPH.  
Figure 5B shows average values of Δ[DA] for each 5 min-epoch. One-way repeated 
measures ANOVA revealed a significant effect of time for Design 2a (left panel; F11,77 = 14.03, p 
< 0.0001) and Design 2b (right panel; F11,33 = 22.7, p = 0.0115). Per the analysis of [DA]max and 
DA transients, the time series of Δ[DA] was compiled into drug groups with a single control in 
Figure 5C. One-way repeated measures ANOVA with pseudo-replication revealed a significant 
effect of drug on Δ[DA] for Design 2a (left panel; F3,9 = 86.59, p < 0.0001) and Design 2b (left 
panel; F3,9 = 9.03, p < 0.0044). However, post-hoc tests revealed that only AMPH caused a 
significant increase in Δ[DA] with Design 2a (left panel; p < 0.0001) and Design 2b (right panel; 
p = 0.0059). Taken together, these results suggest that ATX does not alter basal DA levels in the 
striatum. 
Discussion 
The goal of the present study was to investigate the effects of the non-stimulant ADHD 
drug, ATX, on striatal DA signaling measured in real time using FSCV at a CFM. ATX did not 
alter electrically evoked phasic-like DA signals and basal DA levels, consistent with a lack of 
presynaptic effects on DA terminals in the ventral striatum. However, and indicative of proximal 
effects involving an activation of burst firing by DA neurons, ATX elicited DA transients. 
Collectively, these results suggest that, in addition to well-recognized actions of elevating NE and 
DA levels in the PFC, activation of phasic DA signaling in the ventral striatum is a potential 
mechanism by which ATX elicits therapeutic effects for treatment of ADHD. 
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ATX and electrically evoked phasic-like DA signals 
Electrically evoked DA signals measured in real-time by FSCV at a CFM reflect the 
opposing actions of exocytotic DA release and DA uptake (Wightman et al., 1988). The 
electrically evoked DA responses evaluated in this study also mimic the amplitude and dynamics 
of naturally occurring DA transients (Robinson et al., 2008). Thus, because ATX did not alter 
[DA]max and the dynamics of these electrically evoked responses, we conclude that ATX does not 
presynaptically alter phasic DA signaling in the ventral striatum. In contrast, the D2 DA receptor 
antagonist, RAC, increased [DA]max and the duration of these electrically evoked phasic-like DA 
signals. The effects of RAC are consistent with blockade of presynaptic DA autoreceptors in the 
ventral striatum and the subsequent increase in DA release and decrease in DA uptake (Wu et al., 
2002). Similarly, although not further increasing [DA]max above RAC levels significantly, AMPH 
also increases DA release and decreases DA uptake (Avelar et al., 2013; Covey et al., 2013; 
Daberkow et al., 2013). 
Our results with ATX are in alignment with the high selectivity of ATX for NET and its 
low binding affinity to DAT (Bymaster et al., 2002). Anatomical studies have demonstrated that 
the ventral striatum receives noradrenergic projections from the locus coeruleus (LC) (Berridge et 
al., 1997), as well as from the nucleus tractus solitarius (NTS) (Delfs et al., 1998). Extracellular 
DA released in the ventral striatum may be non-preferentially cleared by NET similar to the PFC 
(Yamamoto & Novotney, 1998). However, the ventral striatum is predominantly innervated by 
VTA DA neurons and thus, has a greater population of DAT as compared to NET. Therefore, the 
relative abundance of DAT in the ventral striatum, coupled with the high selectivity of ATX for 
NET, is presumably the cause for negligible ATX effects on [DA]max and the duration of 
electrically evoked phasic-like DA signals recorded in the ventral striatum. 
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ATX and basal DA levels 
Our study with FSCV at a CFM coupled to the chemometrics approach of PCR showed no 
significant ATX-induced changes in basal DA levels in the ventral striatum. This result concurs 
with previous microdialysis results, which showed no increase in dialysate DA collected in the 
nucleus accumbens with ATX (Bymaster et al., 2002) and other selective NET inhibitors, such as 
desipramine and reboxetine (Linner et al., 2001). Similar to results with electrically evoked 
phasic-like DA signals, the lack of effect of ATX on basal DA levels is inconsistent with a 
presynaptic target of DA terminals in the ventral striatum. Similar to ATX, RAC showed no 
significant effects on Δ[DA], while AMPH significantly increased this FSCV measure of basal 
DA levels. These later results are not entirely consistent with previous microdialysis studies, 
which have shown that both drugs elevate striatal dialysate DA (Hertel et al., 1999; Kuczenski et 
al., 1991). The basis for this discrepancy is not entirely clear but must be related to different 
analytical properties of the monitoring techniques. Microdialysis exhibits excellent chemical 
resolution and sensitivity, but its large probe damages adjacent tissue confounding quantitative 
studies (Borland et al., 2005; Watson et al., 2006). On the other hand, FSCV provides superior 
temporal and spatial resolution but is more limited by sensitivity and selectivity and hence, 
requires coupling with PCR to resolve DA from interferents (Keithley & Wightman, 2011). Recent 
studies in the mouse striatum have suggested basal DA levels to be approximately 100 nM 
(Atcherley et al., 2014). Because FSCV coupled to PCR has detected changes in basal DA in the 
lower nanomolar ranges (~5 to 40 nM; (Hart et al., 2014), this approach appears to be suitable for 
investigating the effects of ATX on basal DA levels. 
  
16 
ATX activates DA transients in the ventral striatum 
Here we show that ATX, a selective NET blocker, elicits DA transients in the ventral 
striatum. Because ATX appears devoid of presynaptic effects on DA terminals in the ventral 
striatum, this result is consistent with an upstream action involving the activation of burst firing 
by DA neurons (Sombers et al., 2009). Indeed, the functional correlation between burst firing of 
DA neurons and the appearance of DA transients in DA terminal fields is well established through 
studies with behaving animals in response to rewards and reward-predicting cues (Schultz, 1998; 
Covey et al., 2013; Clark et al., 2010; Covey et al., 2014) and also with psychostimulants, such as 
cocaine and AMPH (Shi et al., 2000; Shi et al., 2004; Stuber et al., 2005; Koulchitsky et al., 2012; 
Daberkow et al., 2013). Previous studies have also shown other selective NET inhibitors to induce 
burst firing in VTA DA neurons (Shi et al., 2000; Linner et al., 2001; Friedman et al., 2008), 
perhaps mediated indirectly by the PFC and/or directly within the VTA (Darracq et al., 1998; 
Grenhoff et al., 1993; Grenhoff & Svensson, 1993). Confidence in the present ATX-induced 
activation of DA transients is supported by the excellent agreement between the observed lack of 
activation of DA transients by RAC alone in the anesthetized preparation but an increase after 
subsequent administration of psychostimulant, i.e., AMPH, and previous studies (Venton & 
Wightman, 2007; Park et al., 2010). Taken together, our results suggest that ATX, a non-stimulant, 
thus shares activation of phasic DA signaling with psychostimulants such as AMPH and cocaine. 
Although our study does not elucidate the precise mechanism of action by which ATX 
elicits DA transients, there is evidence supporting a few possible explanations. By inhibiting NET, 
ATX elevates extracellular NE levels in the PFC, which receives dense noradrenergic input from 
the LC (Ferrucci et al., 2013). Increased cortical NE activates the post-synaptic α-1 adrenergic 
receptors and causes excitation of PFC neurons. The subsequent post-synaptic excitatory effect of 
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cortical glutamatergic afferents to the VTA can cause burst firing of DA neurons (Thierry et al., 
1979; Sesack & Pickel, 1992; Karreman & Moghaddam, 1996; Darracq et al., 1998). Supporting 
this hypothesis are reports showing that stimulation of PFC neurons selectively increases burst 
firing in the VTA and enhances DA release in the nucleus accumbens (Murase et al., 1993; Taber 
et al., 1995), whereas application of glutamate receptor antagonist decreases extracellular DA 
levels in this ventral striatal region (Taber et al., 1995). Furthermore, the VTA receives direct 
noradrenergic innervation from the LC (Jones & Moore, 1977; Grenhoff et al., 1993) and other 
brain stem regions (Mejias-Aponte et al., 2009). Direct application of NE depolarizes ~60% of the 
DA neurons in the VTA (Grenhoff et al., 1995). Additionally, DA neuron firing increases in 
response to single-pulse stimulation of the LC and is attenuated in the presence of prazosin 
(Grenhoff et al., 1993; Grenhoff & Svensson, 1993). Thus, by blocking NE uptake at 
noradrenergic terminals, and thereby increasing extracellular levels of NE in the NET rich PFC, 
as well as in the VTA, ATX may be mediating an excitatory effect on the VTA DA neurons, 
leading to their phasic activation. 
Therapeutic action of ATX in ADHD 
The activation of DA transients in the ventral striatum by ATX may have important 
implications to its relevance as an ADHD drug within the purview of the DTD model. It is 
suggested that psychostimulant drugs, like AMPH (Adderall®) and MPH (Ritalin®), used to treat 
ADHD produce their therapeutic effects by increasing the amplitude of the DA transient elicited 
by the predictive cue and/or the reward during reinforcement learning (Tripp & Wickens, 2008). 
This enhanced transient activation would in turn improve associative learning between cue and 
reward, which is hampered in ADHD patients. Thus, activation of phasic DA signaling may be an 
additional contributing factor to the therapeutic effects of ATX in treatment of ADHD. However, 
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an important caveat to consider is ATX dose. The dose of ATX that we used (10 mg/kg) was 
selected, because it robustly elevates dialysate DA levels in the PFC but not in the dorsal striatum 
and nucleus accumbens (Bymaster et al. 2002). Previous reports with other selective NET 
inhibitors, nisoxetine (Shi et al., 2000; Shi et al., 2004) and reboxetine (Linner et al., 2001), have 
also used i.v. administration at similar doses to demonstrate an activation of burst firing of 
midbrain DA neurons. However, the dose of 10 mg/kg for ATX may not be therapeutically 
relevant and hence, the precise pharmacologic implications of ATX for treating ADHD needs 
further study, especially using awake animals due to the blunting effects of anesthesia on burst 
firing of DA neurons (Kelland et al., 1990; Chiodo, 1988). 
Conclusion 
Here we show, for the first time, that ATX, a selective NET-inhibitor, elicits DA transients 
in the ventral striatum. Hence, activation of phasic DA signaling may be a common property of 
ADHD drugs. Eliciting DA transients, which are the extracellular phasic signals important for 
reward processing and reinforcement learning, may be a possible additional mechanism of ATX 
in causing its therapeutic effects in ADHD. However, this suggestion must be confirmed by further 
study using therapeutic doses of ATX in freely behaving animal models. 
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Figure 1. Experimental design and data analysis. A) Experimental Design 1 for i.p. drug 
administration. Electrical stimulation is indicated by black arrows; drug injection is 
indicated by blue arrows. Design 1a: Three pre-drug electrically evoked signals were 
collected, followed by administration of ATX. After collecting a 60-min post-ATX trace, 
RAC was injected. Collection of the 60-min post-RAC trace was follwed by administration 
of the positive control, AMPH, co-administered with a second dose of RAC. Design 1b: 
Similar to Design 1a, except that the order of administration of RAC and ATX was 
reversed. B) Experimental Design 2 for i.v. drug administration. Electrical stimulation is 
indicated by black arrows; drug injection is indicated by blue arrows. Design 2a: Three 
pre-drug electrically evoked signals were collected, followed by administration of SAL, 
which was the negative control. ATX was injected after the 10-min post-SAL trace, 
followed by admistration of RAC and AMPH (positive control). Design 2b: Similar to 
Design 2a, except that the order of administration of RAC and ATX was reversed. C) (Top) 
FSCV (black line) and PCR (red line) traces for exemplar recordings pre- (left) and post- 
(right) AMPH. (Bottom) Pseudo-color plots for both representative recordings showing 
multiple analytes in the non-electrically evoked portion. The PCR resolved trace was used 
to analyze changes in basal DA (Δ[DA]). Below is a 20-s representative recording showing 
DA transients in the non-electrically evoked portion of the 5-min post-AMPH epoch. The 
PCR-resolved DA trace was used to analayze DA transients. (INSET, Top) DA transients 
on the PCR trace are denoted by red asterisks. (INSET, Bottom) Pseudo-color plot 
confirms identity of the analyte as DA. D) An exemplar electrically evoked DA signal 
determined from the raw FSCV signal was used to determine the maximal amplitude of 
the electrically evoked DA signal ([DA]max). 
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Figure 2. Effects of ATX, RAC, and AMPH (i.p) on electrically evoked phasic-like DA 
signals. A) (Top) DA signals elicited by electrical stimulation: pre-drug, post-RAC, post 
ATX, and post-AMPH (left to right). INSET. Individual voltammograms taken from the peak 
signal (white vertical line on the pseudo-color plot) identify the analyte as DA. (Bottom) 
Pseudo-color plots of electrically evoked DA signals collected pre-drug, post-RAC, post-
ATX, and post-AMPH (left to right). White horizontal line on the pseudo-color plot identifies 
the DA peak oxidative potential where the evoked DA trace was collected. B) average 
[DA]max. One-way repeated measures ANOVA revealed a significant effect of drug on 
[DA]max in Design 1a (left panel) and 1b (right panel). Data are expressed as a percent of pre-
drug and are mean ±SEM.*, p < 0.05. C) Effects of ATX, RAC, and AMPH (i.p) on DA 
transients. Representative pseudo-color plots of the non-electrically evoked portion of pre-
drug, RAC, ATX, and AMPH recordings (left to right). INSET. Normalized voltammograms 
taken from the electrically-evoked response (black line) and a DA transient or baseline (red 
line) collected at the white vertical line in the pseudo-color plot. 
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Figure 3. Effects of SAL, ATX, RAC, and AMPH on electrically evoked phasic-like DA signals. 
A) (Top) DA signals elicited by electrical stimulation: SAL, ATX, RAC, and AMPH (left to 
right). INSET. Individual voltammograms taken from the peak signal (white vertical line in the 
pseudo-color plot) identify the analyte as DA. (Bottom) Pseudo-color plots of electrically 
evoked DA signals SAL, ATX, RAC, and AMPH (left to right). White horizontal line in the 
pseudo-color plot identifies the DA peak oxidative potential where the evoked DA trace was 
collected. B) One-way repeated measures ANOVA revealed a significant effect of time on 
[DA]max in Design 2a (left panel) and 2b (right panel). Data are expressed as a percent of pre-
drug and are mean ±SEM. C) One-way repeated measures ANOVA revealed a significant 
effect of drug on [DA]max in Design 2a (left panel) and 2b (right panel). Data are expressed as 
a percent of pre-drug and are mean ±SEM.*, p < 0.05. 
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Figure 4. Effects of SAL, ATX, RAC, and AMPH on DA transients. A) Representative 
recordings of DA transients in the ventral striatum. (Top) Normalized voltammograms taken 
from the electrically-evoked response (black line) and a DA transient or baseline (red line) 
collected at the white vertical line in the pseudo-color plot. (Middle) DA transients (denoted 
by red asterisks) are displayed in the PCR-resolved DA trace. (Bottom) A pseudo-color plot 
underneath serially displays all voltammograms in time. B) One-way repeated measures 
ANOVA showed a significant effect of time on the number of DA transients in Design 2a (left 
panel) and 2b (right panel). Data are mean ±SEM. C) One-way repeated measures ANOVA 
showed a significant effect of drug on the number of DA transients in Design 2a (left panel) 
and 2b (right panel). Data are mean ±SEM.*, p < 0.05. 
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Figure 5. Effects of ATX, RAC, and AMPH on changes in basal DA in the ventral striatum. A) 
(Top) FSCV (black line) and PCR (red line) traces for exemplar recordings: SAL, ATX, RAC, 
and AMPH (left to right). (Bottom) Pseudo-color plots for representative recordings showing 
multiple analytes in the non-electrically evoked portion. The PCR resolved trace was used to 
analyze changes in basal DA. B) One-way repeated measures ANOVA showed a significant 
effect of time on Δ[DA] in Design 2a (left panel) and 2b (right panel). Data are mean ±SEM. 
C) One-way repeated measures ANOVA showed a significant effect of drug on Δ[DA] in 
Design 2a (left panel) and 2b (right panel). Data are mean ± SEM. *, p < 0.05. 
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CHAPTER II 
DOPAMINE TRANSPORTER-INHIBITING PSYCHOSTIMULANTS INCREASE 
EXOCYTOTIC DOPAMINE RELEASE 
ABSTRACT 
There is increasing evidence suggesting that psychostimulants elevate brain extracellular 
dopamine not only by inhibiting dopamine uptake but also by increasing exocytotic dopamine 
release. Psychostimulant-induced increases in exocytotic dopamine release have been 
demonstrated by fitting electrically evoked dopamine signals measured using fast-scan cyclic 
voltammetry at a carbon-fiber microelectrode to the diffusion gap model, which describes 
dopamine diffusing across a gap between release and uptake sites and measurement at the 
microsensor. However, this model fails to describe features regularly observed in evoked 
dopamine signals, such as “hang-up”, the slow return of dopamine to baseline, and incongruous 
changes in “lag”, the time for dopamine to increase after stimulus initiation, and “overshoot”, the 
continued dopamine increase after stimulus cessation. The recently proposed restricted diffusion 
model addresses these issues by dividing extracellular space into inner and outer compartments. 
Dopamine is initially released into the inner compartment and is transported by restricted diffusion 
to the outer compartment, where it is measured by the microsensor and cleared by dopamine 
uptake. Hang-up, attributed to dopamine adsorption to the microsensor, is removed from data prior 
to analysis. Here we analyze the in vivo effects of the psychostimulants, amphetamine, cocaine, 
and modafinil, on exocytotic dopamine release and dopamine uptake. Parameters describing these 
mechanisms and previously determined with the diffusion gap model were compared to those 
obtained by the restricted diffusion model. Both models similarly demonstrated an increase in 
exocytotic dopamine release and inhibition of dopamine uptake for all three psychostimulants. 
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These results support the hypothesis that psychostimulants elevate extracellular dopamine by 
targeting both exocytotic dopamine release and dopamine uptake. 
INTRODUCTION 
The mechanism of psychostimulant action has been the subject of intense scrutiny over 
the years. These drugs cause their behavioral effects, at least in part, by elevating extracellular DA 
in the dorsal and ventral striatum (Carboni et al., 1989; Di Chiara & Imperato, 1988; Carboni et 
al., 1989). A well-established action of one class of psychostimulants is inhibition of the dopamine 
transporter (DAT), which regulates extracellular DA levels by clearing released DA. Based on 
their interactions with DAT on DA terminals, psychostimulants have been classified as being 
cocaine-like or amphetamine (AMPH)-like. Cocaine-like drugs are traditional inhibitors of DAT, 
whereas AMPH-like drugs are DAT “substrates” (Seiden et al., 1993). AMPH-like 
psychostimulants are also referred to as “releasers”, due to their property of eliciting reverse 
transport by DAT thereby causing non-action potential-dependent DA efflux (Sulzer et al., 1995). 
While both cocaine-like and AMPH-like drugs share the mechanism of competitive inhibition of 
DA uptake, these psychostimulants have been thought to differ in their actions on vesicular pools 
of DA and exocytotic DA release. Whereas cocaine has been shown to augment exocytotic DA 
release (Jones et al., 1995; Venton et al., 2006), AMPH depletes vesicular DA pools and hence, 
compromises exocytotic DA release (Jones et al., 1998; Schmitz et al., 2001). Therefore, DAT 
inhibition and DA efflux driven by translocation of DA from vesicular to cytosolic pools have 
been considered to be the predominant effects of AMPH action contributing to its elevation of 
extracellular levels of striatal DA (Sulzer, 2011; Fleckenstein et al., 2007). Evidence from some 
psychostimulant studies are in support of the hypothesis that in addition to blocking DA uptake, 
psychostimulants also increase exocytotic DA release. These studies report increased exocytotic 
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DA release with methylphenidate (MPH) and other DAT blockers, such as nomifensine (Venton 
et al., 2006; Chadchankar et al., 2012; Lee et al., 2001), in addition to cocaine (Jones et al., 1995; 
Venton et al., 2006). However, AMPH enhancing exocytotic DA release still remains a 
controversial idea due to discrepant results obtained from in vitro (Jones et al., 1998; Schmitz et 
al., 2001) and in vivo studies (Daberkow et al., 2013; Ramsson et al., 2011). 
Kinetic analysis of electrically evoked DA signals measured by fast scan cyclic 
voltammetry (FSCV) at a carbon fiber microelectrode (CFM) has been used to assess the action 
of psychostimulants on DA release and uptake. The Wightman model, also known as the diffusion 
gap (DG) model, has been typically used. The DG model describes extracellular DA concentration 
as a balance between the opposing actions of DA release and uptake (Wightman et al., 1988). The 
DA measurement with FSCV is also subject to the diffusional distortions, lag (i.e., the delay in 
rise of the DA signal with stimulus onset) and overshoot (i.e., the continued rise of DA signal after 
stimulus cessation), arising from the presence of a gap between DA release and uptake sites on 
terminals and the CFM (Wightman et al., 1988; Kawagoe et al., 1992) (Fig. 1a). Using the DG 
model, we have previously reported that the psychostimulants, modafinil (MOD), AMPH, and 
cocaine, not only inhibit DA uptake but also increase action potential-dependent, vesicular DA 
release (Ramsson et al., 2011; Daberkow et al., 2013; Covey et al., 2013; Bobak et al., 2016). 
However, demonstrated insufficiencies in the DG model have challenged its appropriateness and 
hence, the finding of enhanced DA release with psychostimulants. For example, the DG model 
does not hold true for DA signals that show lag without overshoot or overshoot without lag 
(Moquin & Michael, 2009; Walters et al., 2014). The concept of a diffusion gap also fails to 
explain another feature regularly observed in DA signals, called hang-up or the prolonged 
elevation of the signal and its delayed return to baseline (Walters et al., 2014).  
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A new kinetic model, called the restricted diffusion (RD) model, has been recently 
developed (Walters et al., 2015; Walters et al., 2014) to address limitations with the DG model. 
The RD model (Fig. 1b) divides brain extracellular space into inner and outer compartments, with 
DA released into the inner compartment and transported by restricted diffusion to the outer 
compartment where it is detected by the CFM and cleared by uptake. The restricted diffusion of 
DA from the inner to outer compartment could be due to several factors, such as pockets of 
extracellular dead space, DA binding sites, and tissue tortuosity (Sykova & Nicholson, 2008). The 
model convincingly explains lag as a consequence of DA being held up, or restricted, as it diffuses 
to the outer compartment after release, and overshoot as the delayed arrival of DA to the CFM 
after overcoming the diffusional restrictions in its path. Through this concept of delayed DA 
transport from the release site to the CFM, the RD model also effectively provides plausible 
scenarios for the fast and slow-type responses recorded in the rat dorsal striatum, which are not 
always amenable to description by the DG model (Taylor et al., 2013; Walters et al., 2014). 
Additionally, hang-up has been attributed to adsorption of DA to the CFM surface and can be 
corrected using an equation expressing the hang-up component as a balance between the 
concentration of DA adsorbed and desorbed (Walters et al., 2015). Hence, the RD model improves 
the kinetic analysis of electrically evoked DA signals to resolve the presynaptic mechanisms of 
DA release and uptake. 
The purpose of this study was to compare the analysis of psychostimulant effects on 
electrically evoked DA signals measured by FSCV at a CFM using the DG and RD models. 
Specifically, we used the RD model to re-analyze already published electrically evoked DA 
signals altered by MOD, AMPH, and cocaine and evaluated by the DG model. Our results support 
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the hypothesis that the DAT-inhibiting psychostimulants, AMPH, cocaine, and MOD, also 
augment action potential-dependent, exocytotic DA release. 
RESULTS AND DISCUSSION 
Correction of raw FSCV signals 
As described in Figure 2, correction for the hang-up component was required for most 
electrically evoked DA signals kinetically analyzed by the RD model. The pseudo-color plot (Fig. 
2A) suggests that the raw FSCV signal (black line), representing the electrically evoked signal 
(Fig. 2B) and measured at the peak oxidation potential for DA (indicated by horizontal white line 
on the pseudo-color plot), originates from DA. The individual voltammogram (Fig. 2A inset), 
determined at the peak of the evoked signal (indicated by the vertical white line on the pseudo-
color plot), is also consistent with DA. This raw FSCV trace shows the hang-up component (i.e. 
it does not return quickly to baseline), because DA uptake would lower extracellular DA faster. 
To correct for hang-up, this component was first calculated using Eq. 4, which uses first-order 
rate constants to describe hang-up as a balance between DA adsorption to and desorption from the 
CFM surface. The calculated hang-up component (Fig. 2B; gray line) was then subtracted from 
the raw response measured by FSCV (black line) to generate a corrected signal (red line). It is 
noteworthy that previous uses of the DG model described herein did not involve any hang-up 
correction. However, the signals that were analyzed using this model were routinely cut off in 
time to avoid distortion by the hang-up component. 
When present, the effect of pH on the raw FSCV signal, usually an alkaline shift due to 
changes in blood flow elicited by the same electrical stimulation evoking DA release in urethane-
anesthetized animals (Robinson et al., 2003; Venton et al., 2003), was removed using the 
differential correction method (Venton et al., 2003). As can be seen in pseudo-color plot of Figure 
39 
3A, electrical stimulation elicits electrochemical features other than DA, the most prominent of 
which is pH. As shown in Figure 3B, the raw electrically evoked FSCV signal (black line) is 
distorted by this pH signal, which is highlighted by a considerable drop below baseline. The 
identity of the analytes elicited by electrical stimulation is perhaps more clearly demonstrated by 
their respective individual voltammograms. For example, the initial signal elicited by electrical 
stimulation is indicative of DA (Fig. 3A inset, left; voltammogram determined by the first vertical 
white line). Slower changes in the record were confirmed as pH (Fig. 3A inset, right; 
voltammogram determined by the second vertical white line). To correct for pH, its 
voltammogram was determined a few seconds after stimulation and in the absence of any DA 
release and used to calculate a pH signal (Fig. 3B; blue line). This signal, after adjusting to 
correspond to the DA oxidative potential, was then subtracted from the raw FSCV to calculate a 
pH-corrected DA signal (Fig. 3B; red line). This correction has also been applied previously to 
evoked DA signals subject to analysis by the DG model. The pH subtracted signals can then be 
corrected for hang-up (Fig 3B; gray line), as described above, before fitting to the RD model. 
Another method that is used to resolve mixed pH and DA signals collected by FSCV is 
principal component regression (PCR), a chemometrics approach (Heien et al., 2005). However, 
pH change is not always the sole contributor to the measured signal, which may also be affected 
by interferents such as background drift and other analytes in solution. Figure 4 shows the PCR-
resolved components of the same signal that was pH-corrected in Figure 3. The raw FSCV signal 
(black line), which reflects contributions from multiple analytes, is resolved into its principal 
components by PCR, to obtain DA (red line), pH (blue line), and background drift (green line). 
The DA trace resolved from the PCR can be subsequently used for hang-up correction (gray line). 
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Restricted diffusion model with hang-up correction produces better fits 
Figure 5 compares a representative analysis of electrically evoked DA signals altered by 
MOD (300 mg/kg) using the traditional kinetic approach, the DG model, and a new kinetic 
approach, the RD model with hang-up correction. Recordings in the top panel of Figure 5A show 
exemplar DA signals elicited by stimulation of the medial forebrain bundle (MFB) and measured 
by FSCV at a CFM (left panel, pre-drug; right panel, MOD). Pseudo-color plots shown below and 
the individual voltammograms (inset) collected at the time of peak signal (vertical white lines on 
the pseudo-color plot) confirm the evoked signal (horizontal white line on the pseudo-color plot) 
as DA. Administration of MOD, a wake-promoting psychostimulant (vide infra), caused a marked 
increase in the amplitude and broadening of the electrically evoked DA signal as compared to the 
pre-drug signal. As shown in Figure 5B the RD model with hang-up correction did indeed produce 
fits that describe data with higher fidelity than the DG model. We subsequently quantitatively 
compared the effects of MOD, cocaine, and AMPH on electrically evoked DA signals using the 
DG model and RD model with hang-up correction.  
MOD alters DA release and uptake in the dorsal striatum of anesthetized rats 
Developed to treat narcolepsy (Bastoji & Jouvet, 1988), MOD is approved for the 
treatment of sleep-related disorders, such as obstructive sleep apnea and shift-work sleep disorder. 
Its therapeutic effects have also been investigated for treating the psychiatric disorders of attention 
deficit hyperactivity disorder (Swanson et al., 2006) and depression, and drug abuse (Anderson et 
al., 2009; Anderson et al., 2012). Although MOD acts on various neurotransmitter systems, 
including orexin, serotonin, glutamate, and GABA, its action on DA has gained importance over 
time. MOD has been classified as a DAT-inhibiting psychostimulant with low abuse potential 
(Myrick et al., 2004; Deroche-Gamonet et al., 2002). While preventing DA uptake by inhibition 
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of DAT has been considered to be its primary mode of action, recently MOD has also been shown 
to activate phasic DA signaling, which is suggested to be an additional mechanism contributing 
to its clinical effects (Bobak et al., 2016). 
We have previously used the DG model to investigate the effects of MOD on electrically 
evoked phasic DA signals (Bobak et al., 2016). The evoked signals are considered phasic-like 
because of their resemblance to the naturally occurring phasic DA transients associated with 
reinforcement learning and elicited by burst firing of DA neurons (Covey et al., 2014). Our study 
demonstrated that MOD, in a time- and dose-dependent fashion, increased the amplitude of these 
evoked DA signals and DA release and decreased DA uptake. Data showing the effects of MOD 
at a dose of 300 mg/kg on DA release and uptake are replicated in Figure 6A and B (left) for the 
pre-drug condition and 30 and 60 min post-drug. This data sub-set was statistically re-analyzed 
using two-way repeated measures ANOVA for the present study. In excellent agreement with 
Bobak et al. (2016), there was a significant drug-by-time interaction for [DA]p (F2,18 = 20.19, p < 
0.0001), which is the index of DA release, and k (F2,18 = 14.73, p = 0.0002), the first-order rate 
constant for DA uptake. Post hoc tests also demonstrated that MOD significantly increased [DA]p 
(p < 0.0001 at 30 and 60 min) and decreased k (30 min: p = 0.016; 60 min: p = 0.0004), at both 
time points after drug administration. 
We analyzed the same electrically evoked DA signals with the RD model and hang-up 
correction to determine the effects of MOD on DA release and uptake (Figure 6) and also used 
two-way repeated measures ANOVA for statistical comparisons. A significant drug-by-time 
interaction on Rp (F2,18 = 17.62, p < 0.0001), the term for DA release, and kU (F2,18 = 3.68, p = 
0.0456), the term for DA uptake, was seen for the 3-parameter fit (Fig. 6A and B, middle). Similar 
effects were observed on Rp (F2,18 = 16.85, p < 0.0001) and kU (F2,18 = 7.74, p = 0.0038) for the 4-
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parameter fit (Fig. 6A and B, right). The 4-parameter fit of the RD model is the 3-parameter fit 
(i.e., Rp, kU, and kT, the transport rate constant between compartments) with the addition of kR, a 
rate constant reflecting short-term changes in DA release (see Figure 1 and Methods for details). 
Post hoc tests showed a significant MOD-induced increase in Rp compared to vehicle at 30 (p = 
0.0003) and 60 min (p < 0.0001) for the 3-parameter fits (Fig. 6A, middle). Similar results were 
seen for increased Rp with the 4-parameter fits at 30 (p = 0.0012) and 60 min (p < 0.0001) post-
MOD (Fig. 6A, right). As shown in Figure 6B (middle), 3 parameter-fits showed a significant 
MOD-induced decrease in kU compared to vehicle at both time points post-drug (30 min: p = 
0.0456 and 60 min: p = 0.0197). However, the 4-parameter fits for kU (Fig. 6B, right) showed a 
significant difference from vehicle only at 60 min post-drug (p = 0.0043). 
Overall, we did not observe any significant changes in the other two parameters, kT, the 
transport rate constant between compartments, and kR, the rate constant reflecting short-term 
changes in DA release (Fig. S1). Thus, our results with the RD model concur with Bobak et al. 
(2016), which used the DG model, and support the notion that not only does MOD decrease DA 
uptake, it also increases exocytotic DA release. 
Fitting of PCR-treated data 
The electrically evoked DA signals collected pre-drug and 30-min post-MOD and 
described above were used to assess whether PCR processing with hang-up correction altered 
analysis by the RD model (Fig. 7). These data were statistically analyzed using two-way repeated 
measures ANOVA. Similar to unprocessed data, PCR-treated data showed a significant drug-by-
time interaction for Rp with the 3-parameter fit (Fig. 7A, left; F1,6 = 23.25, p = 0.0029) and 4-
parameter fit (Fig. 7A, right; F1,6= 21.6, p = 0.0035), and for kU with the 3-parameter fit (Fig. 7B, 
left; F1,6 = 22.4, p = 0.0032) and 4-parameter fit (Fig. 7B, right; F1,6 = 22.14, p = 0.0033). Post hoc 
43 
tests showed a significant increase in Rp (3-parameter fit: p = 0.0015, 4-parameter fit: p = 0.0039, 
Figure 7A, right and left, respectively). PCR-treated signals also showed a significant decrease in 
kU (3-parameter fit p = 0.0062, 4-parameter fit: p =0.0062, Figure 7B, left). Taken together, these 
results suggest that PCR processing of raw FSCV signals is appropriate for the analysis of DA 
release and uptake parameters using the RD model. 
AMPH alters DA release and uptake in the dorsal striatum of freely behaving rats 
The psychostimulant AMPH is a potent DAT-inhibitor that competitively blocks DA 
uptake and also causes non-exocytotic DA efflux through DAT reversal (Kuczenski and Segal, 
1994; Fleckenstein at al., 2007). Historically, high-dose AMPH is thought to disrupt phasic DA 
signaling, the action potential-dependent transient increases in extracellular DA levels elicited by 
burst firing of DA neurons (Schultz, 2007), by depletion of vesicular stores of DA, which in turn 
compromises exocytotic DA release (Hyman et al., 2006; Sulzer, 2011). However, conflicting 
reports regarding AMPH action have previously been obtained from in vitro (Jones et al., 1998; 
Schmitz et al., 2001) and in vivo (Kuhr et al., 1985; May et al., 1988) preparations, as well as from 
microdialysis (Carboni et al., 1989; Kuczenski et al., 1991) and voltammetric studies (Wiedemann 
et al., 1990). The basis for these discrepant results is difficult to fully understand, but it should be 
considered that the in vivo preparation better replicates natural physiological responses and that 
microdialysis suffers from the disadvantages of low temporal resolution and a large probe that 
damages adjacent tissue, making it difficult to quantify DA levels. More recently, we have used 
FSCV at a CFM in vivo to study AMPH effects on striatal DA signaling and demonstrated that a 
high dose (10 mg/kg) robustly increased exocytotic DA release and decreased DA uptake in both 
anesthetized (Ramsson et al., 2011) and freely behaving (Daberkow et al., 2013) rats. 
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A sub-set of data previously collected in the dorsal striatum of freely behaving rats during 
pre-drug recording and 5, 10, and 15 min post-AMPH (10 mg/kg) and analyzed with the DG model 
(Daberkow et al., 2013) is replicated in Figures 8A and B (left). These data were statistically re-
analyzed using two-way repeated measures ANOVA. In excellent agreement with Daberkow et 
al. (2013), these results demonstrated a significant drug-by-time interaction for [DA]p (F3,24 = 108, 
p < 0.0001), representing DA release (Fig. 8A left), and k (F3,24 = 18.37, p < 0.0001), representing 
DA uptake (Fig. 8B, left). AMPH also increases [DA]p and decreased k at every time point (p < 
0.05). 
We used the 3- and 4-parameter fits of the RD model (Figs. 8A and B, middle and right, 
respectively) and two-way repeated measures ANOVA to assess the same data. Statistical analyses 
showed a significant drug-by-time interaction for Rp with the 3-parameter fit (Fig. 8A, middle; 
F3,24 = 49.75, p < 0.0001) and 4-parameter fit (Fig. 8A, right; F3,24 = 17.2, p < 0.0001), and for kU 
with the 3-parameter fit (Fig. 8B, middle; F3,24 = 24.97, p < 0.0001) and 4-parameter fit (Fig. 8B, 
right; F3,24 = 7.71, p = 0.001). Post hoc tests showed that AMPH significantly increased Rp and 
decreased kU at all time points after drug administration for both the 3- and 4-parameter fits (p < 
0.0001). While we did not observe any significant changes in the kR for the 4-parameter fit, kT was 
significantly decreased for both the 3- and 4-parameter fits (Fig. S2; also see next section). The 
present analysis with the RD model is thus consistent with our previous analysis using the DG 
model (Daberkow et al., 2013) and supports the conclusion that in addition to mechanisms such 
as DA uptake inhibition, DAT reversal, and DA efflux, AMPH elevates extracellular DA in the 
brain through exocytotic DA release. 
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AMPH and cocaine alter DA release and uptake in the dorsal striatum of anesthetized rats 
We have previously compared the effects of cocaine, which is not thought to deplete 
vesicular DA stores, and AMPH, which historically is thought to deplete vesicular DA stores, to 
better understand our paradoxical results showing AMPH enhancing exocytotic DA release in 
awake rats (Daberkow et al., 2013). Overall, these studies demonstrated that both cocaine and 
AMPH activated phasic dopamine signaling in the form of DA transients, increased DA release, 
and decreased DA uptake in the dorsal striatum of anesthetized rats (Ramsson et al., 2011; Covey 
et al., 2013). Thus, in contrast to the widely accepted view that AMPH and cocaine elicit opposite 
effects on exocytotic DA release and phasic DA signaling, data from our lab showed that 
augmentation of action-potential dependent, vesicular DA release was a common property of both 
psychostimulants. 
A sub-set of data from Covey et al. (2013) and showing the effects of AMPH (10 mg/kg) 
and cocaine (40 mg/kg) on DA release and uptake in anesthetized rats as determined by the DG 
model is replicated in Figures 9A and B, respectively (left). These data were statically re-analyzed 
using two-way repeated measures ANOVA. Consistent with Covey et al. (2013), these results 
demonstrated a significant drug-by-time interaction for [DA]p (F2,16 = 30.89, p < 0.0001), 
representing DA release (Fig. 9A top left), and k (F2,16 = 234.1, p < 0.0001), representing DA 
uptake (Fig. 9A and B, left). Both psychostimulants significantly increased [DA]p and decreased 
k compared to saline controls (p < 0.05). 3- and 4-parameter RD fits of these same data revealed 
a significant drug-by-time interaction for the 3-parameter (Fig. 9a, top middle: F2,16 = 46.3; p < 
0.0001) and 4-parameter (Fig. 9B, right: F2,16 = 8.36; p = 0.0033) fit of Rp and for the 3-parameter 
(Fig. 9B, middle: F2,16 = 771.53; p < 0.0001) and 4-parameter (Fig. 9B, right: F2,16 = 664.78; p = 
< 0.0001) fit of kU. Both AMPH and cocaine significantly increased Rp (p = 0.0002) and decreased 
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kU (p < 0.001) compared to saline in the 3-parameter data fits. Similarly, statistical analysis of the 
4-parameter fits showed that Rp was significantly increased by AMPH (p = 0.0117) and cocaine 
(p = 0.0302), and kU was significantly decreased by AMPH (p = 0.0025) and cocaine (p = 0.0205). 
Overall, we also did not observe any significant changes in the other two parameters, kT and kR 
(Fig. S3). The lack of significant effects of AMPH on kT for either the 3- or 4-parameter fits in 
these data collected in anesthetized rats is at odds with significant decreases in kT for data collected 
in awake rats (Fig. S3). While the origin of this difference is not known, it is interesting to 
speculate the movement in the awake rat may have created an additional diffusion path that was 
expressed as a decrease in kT. Taken together, our results with the RD model thus further support 
the hypothesis that both cocaine and AMPH act similarly to increase exocytotic DA release and 
inhibit DA uptake. 
METHODS 
Data 
Data for analyses are from our previously published studies. MOD data (anesthetized rats) 
were from Bobak et al. (2016; 300 mg/kg, n = 6; vehicle, n = 5). AMPH data (freely behaving 
rats) were from Daberkow et al. (2013; AMPH = 10 mg/kg, n = 6; saline, n = 6). AMPH and 
cocaine data (anesthetized rats) were from Covey et al. (2013; AMPH = 10 mg/kg, n= 7; cocaine 
= 40 mg/kg, n = 5; saline, n = 7). With the exception of the study conducted by Daberkow et al. 
(2013), which investigated effects in the dorsal striatum, Bobak et al. (2016) and Covey et al 
(2013) examined dorsal as well as the ventral striatum. However, for the purpose of this 
investigation, we restricted our analyses to data obtained from the dorsal striatum only. 
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Animals 
For all the three studies mentioned, adult Sprague-Dawley rats (250-300g) were used. 
Animals were purchased from Harlan (Indianapolis, IN, USA), and housed in a light-, and 
temperature-controlled vivarium. Access to food and water was provided ad libitum. All 
procedures were in accordance with the National Institutes of Health Guide for the Care and Use 
of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of 
Illinois State University. 
Surgery 
For the anesthetized studies, adult male Sprague-Dawley rats were anesthetized with 
urethane (1.6 g/kg) and mounted in a stereotaxic apparatus. An incision of the scalp was made, 
and skin and fascia removed. Holes were drilled into the skull to implant recording electrodes, one 
stimulating electrode, and one reference electrode. Using stereotaxic coordinates relative to 
bregma (Paxinos & Watson, 1986), the stimulating electrode was placed in the MFB (-4.6 AP, 
+1.4 ML, -7.0 DV), a CFM was placed in the dorsal striatum (+1.2 AP, +3.0 ML, -4.5 DV), and 
the Ag/AgCl reference electrode was placed in the contralateral cortex. The stimulating electrode 
and CFM were lowered and optimized to produce a robust electrically evoked DA signal. The 
position of the electrodes was fixed for the duration of the experiment after optimization. For the 
freely behaving studies, rats were anesthetized with ketamine (80 mg/kg) and xylazine (60 mg/kg) 
injected i.p. before mounting in a stereotaxic frame. Reference and stimulating electrodes and a 
hub to house a micromanipulator were implanted and secured to the skull. During recording in 
awake rats, a fresh CFM was lowered after attaching the micromanipulator and optimized prior to 
the beginning of the experiment. For both studies, the CFMs were prepared by aspirating a single 
carbon fiber (r = 3.5 μm) into a borosilicate capillary tube and pulling to a taper. A chloridized 
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silver wire was used as reference electrode. Twisted bipolar stimulating electrodes, with tips 
spaced ~1 mm apart, were used. Stimulus pulses were optically isolated and delivered at a constant 
current as 60-Hz, 24-pulse trains at a current intensity of ±300 µA. 
FSCV 
Electrically evoked dopamine levels were recorded using FSCV at a CFM. A triangular 
waveform (-0.4 to 1.3 V and back, 400 V/s) was applied every 100 ms. An EI400 bipotentiostat 
(Ensman Instruments, Bloomington, IN, USA), which was computer controlled using TarHeel-1 
software (ESA, Chelmsford, MA, USA), was used to perform FSCV. The CFM was calibrated in 
TRIS buffer after each experiment to convert the peak oxidation current for DA in each scan to a 
concentration (Wightman et al., 2007). 
Data Analysis 
Electrically evoked DA signals were analyzed to determine parameters for exocytotic DA 
release and DA uptake using two kinetic models: 
1.  Diffusion gap model (Fig. 1A). This model postulates that brain extracellular DA 
is governed by the balance between dopamine released and that which is taken back up. To be 
measured, DA must diffuse across a gap between the CFM and releasing DA terminals. The 
mathematical equation describing this is as follows (Wightman et al., 1988; Wu et al., 2001): 


= DA
 − DA    (1) 
where, [DA]p is the concentration of DA released per stimulus pulse, f is the frequency of 
stimulation, and k is the first-order rate constant for DA uptake. Curve fitting of data to Eq. 1 used 
non-linear regression with a simplex minimization algorithm. (Wu et al., 2001). Calculated curves 
were convoluted with an impulse response function for thin layer diffusion prior to data 
comparison (Kawagoe et al., 1992). 
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2.  Restricted diffusion model (Fig. 1B). This model divides the brain extracellular 
space into an inner and an outer compartment, and postulates that DA released into the inner 
compartment diffuses in a restricted manner into the outer compartment, from where it can be 
measured by the CFM and is subject to reuptake. The model comprises two equations (Walters et 
al., 2015): 
dDA
d
= 
 e
 −  DA                                                (2) 
dDA
d
=
DA

 −  DA                                             (3) 
where DAic is the amount (in moles) of DA in the inner compartment, Rp is the moles of DA 
released per stimulus pulse, f is the stimulus frequency, kR is a first-order rate constant that signifies 
modification of DA release by either short-term depression or facilitation, kT is a first order rate 
constant for DA transport from inner to outer compartment, Voc is the volume of the outer 
compartment (fixed at 16 µm3) (Walters et al., 2014; Walters et al., 2015; Moss & Bolam, 2008), 
and kU is the first-order rate constant for DA uptake. 
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Hang up correction 
Before analyses using the RD model, the effect of hang-up was removed from electrically 
evoked DA signals by using a correction as explained in detail by Walters et al. (2015). Briefly, 
the algorithm calculates a hang-up component in terms of first-order rate constants describing the 
balance between DA adsorption to and desorption from the CFM surface. The equation that 
describes this balance is as follows: 
d 
d
=  !" −  ##Γ                                                              (4) 
where kon and koff are first-order rate constants for DA adsorption and desorption, respectively, and 
C is the concentration of DA in solution in close contact with the electrode, which is the same as 
the concentration detected by FSCV (Walters et al., 2015). The calculated hang-up component is 
then subtracted from the measured evoked response, to give a corrected signal. 
A brute-force algorithm was used for curve fitting as described in Walters et al. (2015) and 
Walters et al. (2014). Curve fitting was used to set the values of the adjustable parameters in the 
hang-up (Eq. 4) and DA kinetic (Eqs. 2 and 3) models. The parameters producing the best fit to 
data were those that were defined by high Pearson correlation coefficients and the smallest values 
of the sum of squares of the residuals. 
pH correction 
The effect of basic pH shifts following electrical stimulation, caused by changes in local 
blood flow, was removed by using the voltammogram of the pH change occurring a few seconds 
(~5 s) after stimulation and free of DA. Current for pH (measured typically at ≈-0.2 mV) was then 
adjusted for the DA oxidative potential (≈+0.6 mV typically) before subtracting the pH current 
from the total current measured at the DA oxidative potential. 
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PCR 
For PCR, different number of stimulation pulses (12, 24, 48, 60, and 72 pulses), which 
produce different electrically evoked DA concentrations, were used to construct in vivo training 
sets. From these recordings, five background-subtracted voltammograms for each analyte, DA, 
pH, and background drift, were collected, and the principal components, which account for most 
of the relevant data, were calculated using principal component analysis (PCA). Subsequently, 
each principal component was translated into the corresponding analyte units using least square 
regression. Experimental recordings containing unknown sample concentrations were then 
projected on to the principal components, in order to determine their amplitudes (Hermans et al., 
2008; Keithley et al., 2009). 
Statistics 
When appropriate, data are presented as the mean ± SEM. All statistical analyses were 
performed using SAS. For the MOD (anesthetized rats) and AMPH (freely-behaving rats) studies, 
a repeated-measures two-way ANOVA with drug and time as independent variables and time as 
the repeated measure was used for each parameter. Post hoc comparisons were performed by a 
Sidak test. Effects of AMPH and cocaine (anesthetized rats) were statistically analyzed using a 
one-way ANOVA with a Dunnett’s post hoc test. Significance was set at p < 0.05. 
Drugs and Chemicals 
Urethane, cocaine hydrochloride, and D-amphetamine was purchased from Sigma (St. 
Louis, MO, USA). MOD was provided by Research Triangle Institute-National Institute on 
Drug Abuse, Raleigh, NC. All drugs were administered i.p. 
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CONCLUSION 
The ability to inhibit DA uptake has largely been accepted as the unifying mechanism by 
which DAT-targeting psychostimulants enhance extracellular brain DA levels and cause many of 
their behavioral effects (Sulzer, 2011; Fleckenstein et al., 2007). As compared to other 
psychostimulants in this class, AMPH has been shown to elicit greater extracellular DA 
concentrations, due to its unique action of reversing the direction of DA transport via DAT and 
causing DA efflux. While most of the cocaine-like psychostimulants are also known to activate 
action potential-dependent DA signaling, AMPH has been excluded from causing this effect; 
instead, AMPH disrupts this type of DA signaling by depleting vesicular DA stores and decreasing 
exocytotic DA release (Sulzer, 2011; Hyman, 2005). Indeed, non-action potential-dependent DA 
efflux, driven by the depletion of readily releasable DA stores, has been proposed to be the 
hallmark of AMPH action in the brain. 
Kinetic modeling of electrically evoked DA signals in vivo, measured before and after drug 
administration by FSCV at a CFM, provides valuable information about the effects of DAT-
targeting psychostimulant on the presynaptic mechanisms of DA release and uptake (Wightman 
et al., 1988; Wu et al., 2001). The DG model of kinetic analysis, which attributes the diffusional 
distortions of lag and overshoot to a gap between DA releasing terminals and the CFM, has been 
used to quantitatively resolve the release and uptake components of evoked DA signals. With the 
DG model, previous results obtained by our lab are at odds with the accepted model of AMPH 
action. Indeed, these studies have failed to demonstrate compromised phasic DA signaling due to 
disrupted exocytotic DA release with high-dose AMPH and instead have shown increased phasic 
DA signaling and augmented exocytotic DA release, more consistent with the actions of cocaine 
and cocaine-like DAT inhibitors (Ramsson et al., 2011; Daberkow et al., 2013; Covey et al., 2013). 
53 
Moreover, we have more recently shown that an atypical psychostimulant, MOD, also increases 
DA release (Bobak et al., 2016). However, drawbacks of the DG model, such as its insufficiency 
in describing the discordant appearance of lag and overshoot, and the presence of hang-up in DA 
signals, have rendered its application for DA kinetic analysis debatable, thereby raising questions 
on the finding of psychostimulants augmenting exocytotic DA release. On the other hand, the RD 
model, based on the concept of restricted diffusion of released DA and its delayed detection at the 
CFM, more faithfully describes DA signals in terms of lag, overshoot, and hang-up (Walters et 
al., 2014; Walters 2015). 
This study therefore sought to compare results for the psychostimulants, MOD, AMPH, 
and cocaine, calculated using the DG model with those obtained using the RD model, with a 
particular focus on assessing the previously identified psychostimulant-induced increase in DA 
release. Despite their theoretical differences, both models showed amplified exocytotic DA 
release and decreased DA uptake for all the psychostimulants tested, the latter in keeping with 
their well-recognized role as DAT-inhibitors. We speculate that the reasons for the excellent 
agreement between models is that firstly, all signals fit to the DG model were pre-selected via 
optimization and placement of CFMs close to the DA releasing terminals, which presumably 
downplayed the effect of the diffusion gap distorting measured DA signals. Secondly, while the 
DG model was not coupled to the hang-up correction, this distortion was minimized by fitting the 
early portions of the signals and avoiding the latter portions reflecting the greatest hang-up 
component. 
The major conclusion resulting from this study is that the DAT-targeting 
psychostimulants, AMPH, cocaine, and MOD, elevate extracellular DA concentration not solely 
by DA uptake inhibition, but also by upregulating action potential-dependent DA release. This 
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result is of particular significance with regards to AMPH action, which has historically been 
considered to elevate extracellular DA levels in the brain primarily by vesicular DA depletion 
driving DA efflux. We thus propose that DAT inhibitors are misnamed, because this group of 
psychostimulants may also enhance DA release. Cellular mechanisms of how these 
psychostimulants increase exocytotic DA release have been investigated. Cocaine has been shown 
to mediate its effects of enhancing DA release by mobilizing synapsin-bound DA vesicles, which 
are part of the long-term storage pool (Venton et al., 2006). MPH causes upregulated DA release 
via α-synuclein, a protein involved in vesicular trafficking (Chadchankar et al., 2012). That 
AMPH may act also exert its effects on synaptic proteins is a speculation worth testing. Previously 
results from our lab have demonstrated that AMPH also augments exocytotic DA release by 
increasing DA synthesis and inhibiting DA degradation, presumably leading to increased cytosolic 
DA and vesicular loading (Avelar et al., 2013). 
Augmentation of vesicular DA release is especially important for activation of the DA 
transients of phasic DA signaling, which play a critical role in reinforcement learning, goal-
directed behavior, and drug addiction (Stuber et al., 2005). Evidence from AMPH and MOD 
studies shows that enhanced DA release tracks increases in [DA]max, the maximal amplitude of 
electrically evoked phasic-like DA signals, better than reduced DA uptake (Bobak et al., 2016; 
Covey, et al., 2013; Daberkow, et al., 2013). Assuming that electrically evoked phasic-like DA 
signals mimic naturally occurring DA transients, a higher correlation of [DA]max with exocytotic 
DA release compared to DA uptake indicates that increased exocytotic DA release may be 
responsible for the increased amplitude of DA transients with psychostimulants (Stuber et al., 
2005; Daberkow et al., 2013). The augmentation of exocytotic DA release causing the increased 
amplitude of DA transients may therefore be an important action mediating the abuse potential of 
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addictive drugs. Hence, this study contributes towards establishment a new unifying mechanism 
of action of psychostimulants in activating phasic DA signaling through increased exocytotic DA 
release, in addition to inhibition of DA uptake. This study also highlights the need to reconsider 
and re-assess mechanisms of action of psychostimulants. While most such drugs are potentially 
abusive, many are also used as medication. For example, MOD is a commonly prescribed wake-
promoting agent (Wise et al., 2007), and AMPH and MPH are used in the treatment of attention 
deficit hyperactivity disorder (Swanson et al., 1995). Therefore, it is imperative that a detailed 
understanding of ways in which these drugs act should be explored and elaborated further, in order 
to aid in better drug development and to improve efforts towards controlling drug abuse. 
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CHAPTER II FIGURES
 
 
  
Figure 1. Schematic representation of DG and RD models. In the DG model (left panel), 
released vesicular DA (orange) ([DA]p; f is frequency of stimulation) diffuses through a gap 
(l), before it reaches the detecting CFM and is cleared by DAT through first-order DA uptake 
(k). According to Eq. 1, this model describes extracellular DA levels as a balance between DA 
release and uptake. The RD model (right panel) divides the extracellular space into inner 
compartment (IC) and outer compartment (OC) and postulates that released DA (Rp; kR is a 
first-order rate constant signifying short-term changes in DA release) is transported from IC to 
OC where DA is measured by the CFM and DA uptake take place. The restricted diffusion of 
DA and DA uptake are described by the first-order rate constants, kT and kU, respectively. The 
RD model is comprised of two equations (Eqs. 2 and 3), each defining DA levels in the IC and 
OC, respectively. 
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Figure 2. Hang-up correction of electrically evoked DA signals. A) Pseudo-color plot of an 
exemplar electrically evoked DA signal. (Inset) Individual voltammogram (see vertical while 
line I pseudo-color plot). B) DA concentration obtained from the raw FSCV trace (see 
horizontal white line in the pseudo-color plot) is displayed in black. The hang-up component 
(gray) was calculated and subtracted from the raw signal to produce a hang-up corrected DA 
trace (red). 
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Figure 3. pH correction of electrically evoked DA signals. A) Pseudo-color plot of an exemplar 
electrically evoked DA signal showing basic pH changes (blue portion). (Inset) Individual 
voltammograms identify the analytes as DA (red), at the time point represented by the left 
vertical white line, and pH (blue), at the time point indicated by the right vertical white line of 
the pseudo-color plot. B) Concentration vs. time plots of the DA trace obtained from raw the 
FSCV recording (black line; see upper horizontal white line on the pseudo-color plot) and after 
pH correction (red). The blue line represents the pH current measured at the peak pH potential 
(see lower horizontal white line on the pseudo-color plot). Hang-up subtracted trace (gray) was 
obtained by performing hang-up correction on the pH corrected signal. 
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Figure 4. Hang-up correction of PCR-resolved DA signals. Concentration vs. time plots of the 
PCR-resolved DA trace (red) obtained from raw the FSCV recording (black). PCR also 
resolved the raw signal into principal components for pH (blue) and background drift (green). 
Hang-up subtracted trace (gray) was obtained by performing hang-up correction on the PCR-
resolved DA trace. 
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Figure 5. Comparison of fits obtained by DG and RD models. A) (Top) DA signals elicited by 
electrical stimulation before (left) and 60 min after (right) MOD (300 mg/kg) administration. 
(Inset) Individual voltammograms taken from the peak signal (white vertical line on pseudo-
color plots) identifies the analyte as DA. (Bottom) 15-s pseudo-color plots for the pre- and 
post-MOD evoked signals. White horizontal line identifies the DA peak oxidative potential 
where the evoked DA trace was collected. B) Fits produced for each of these exemplar signals 
using the DG (red line) and RD (blue line) models. The DG model was fit to FSCV data (red 
dots), and the RD model was applied on FSCV data that were hang-up corrected (blue dots). 
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Figure 6. MOD activates exocytotic DA release and reduces DA uptake. A) An increase in the 
DA release parameter from the DG model (left), and the 3-parameter (middle), and 4-parameter 
(right) fits of the RD model was seen in response to administration of MOD (300 mg/kg). B) 
MOD causes a decrease in DA uptake as shown by the reduced uptake parameter of the DG 
(left), and the 3-parameter (middle) and 4-parameter (right) fits of the RD model. Data are 
expressed as a percent of pre-drug and are the mean ± SEM. Data were analyzed for 
significance using two-way repeated measures ANOVA (p < 0.05). 
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Figure 7. MOD increases DA release and reduces DA uptake in PCR-treated DA traces. A) 3-
parameter (left) and 4-parameter (right) fits of the RD model showed that MOD increases Rp 
at 30 min post-drug. B) 3-parameter (left) and 4-parameter (right) fits of the RD model showed 
that MOD significantly reduces kU at 30 min post-drug. Data are expressed as a percent of pre-
drug and are the mean ± SEM. Data were analyzed for significance using two-way repeated 
measures ANOVA (p < 0.05). 
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Figure 8. AMPH activates exocytotic DA release and reduces DA uptake. A) An increase in 
the DA release parameter from the DG model (left), and the 3-parameter (middle) and 4-
parameter (right) fits of the RD model was seen in response to administration of AMPH (10 
mg/kg). B) AMPH caused a decrease in DA uptake as shown in the reduced uptake parameter 
of the DG model (left), and the 3-parameter (middle) and 4-parameter (right) fits of the RD 
models. Data are expressed as a percent of pre-drug and are the mean ± SEM. Data were 
analyzed for significance using two-way repeated measures ANOVA (p < 0.05). 
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Figure 9. Comparison of effects of AMPH and cocaine on DA release and uptake. A) Both 
AMPH and cocaine significantly increased exocytotic DA release as shown by the increased 
release parameter of the DG model (left), and 3-parameter (middle) and 4-parameter (right) fits 
of the RD model. B) AMPH and cocaine reduced DA uptake as shown by the decreased uptake 
parameter of the DG model (left) and 3-parameter (middle) and 4-parameter (right) fits of the 
RD model. Data are expressed as a percent of pre-drug and are the mean ± SEM. Data were 
analyzed for significance using one-way ANOVA (p < 0.05). 
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CHAPTER II SUPPLEMENTARY FIGURES 
S1. Two-way repeated measures ANOVA of DA signals altered by MOD (300 mg/kg) and 
collected in anesthetized rats showed no significant effects of drug, time, and drug-by-time 
interaction on the parameters kT from the 3- and 4-parameter fits, and kR from the 4-parameter fits. 
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S2. Two-way repeated measures ANOVA of DA signals altered by AMPH (10 mg/kg) and 
collected in awake rats showed significant effects of drug (F1,32 = 73.05; p < 0.0001), time (F3,32 
= 27.06; p < 0.0001), and drug-by-time interaction (F3,32 = 20.00; p < 0.0001) on the parameter 
kT for the 3-parameter fits. AMPH was significantly different from vehicle at all time points after 
drug administration (p < 0.0001). 4-parameter fits also showed significant effect of drug (F1,31 = 
95.7; p < 0.0001), time (F3,31 = 40.01; p < 0.0001), and drug-by-time interaction (F3,31 = 44.65; p 
< 0.0001). kR from the 4-parameter fits did not change significantly. 
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S3. Two-way repeated measures ANOVA of DA signals altered by AMPH (10 mg/kg) and 
cocaine (40 mg/kg) and collected in anesthetized rats showed no significant effects of drug, time, 
and drug-by-time interaction on the parameters kT from the 3- and 4-parameter fits, and kR from 
the 4-parameter fits in dorsal striatum of anesthetized rats. 
 
 
 
 
